A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Pasireotide (Primary) ; Sumatriptan
- Indications Cluster headache
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Nov 2016 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 08 Nov 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2019.
- 08 Nov 2016 Status changed from not yet recruiting to recruiting.